|
Reasons
|
Number (%)
|
Days to regimen modification
|
|---|
|
(Median, IQRa)
|
|---|
|
Adverse effects
|
277 (73.5)
|
29 (5-55)
|
|
Lipodystrophy
|
175 (63.2)
|
1493 (936-1946)
|
|
Rash
|
49 (17.7)
|
29 (24-44)
|
|
Hepatitis/Liver dysfunction
|
33 (11.9)
|
146 (56-315)
|
|
Lactic acidosis
|
9 (3.3)
|
511 (410-573)
|
|
Neuropathy
|
8 (2.9)
|
506 (286-574)
|
|
Others
|
3 (1.1)
|
545 (388-1769)
|
|
Treatment failure
|
63 (16.7)
|
1147 (344-1246)
|
|
For TBb treatment
|
16 (4.2)
|
186 (93-248)
|
|
Pregnancy
|
10 (2.7)
|
868 (682-1643)
|
|
Others
|
2 (0.5)
|
527 (62-992)
|
|
Unknown
|
9 (2.4)
|
1085 (527-1705)
|
-
aIQR, interquartile range.
-
bTB, tuberculosis.
